University of Michigan
Ann Arbor, MI, United States
I am a board-certified rheumatologist and Associate Professor of Medicine at the University of Michigan. I have completed a MPH with a focus in epidemiology and health services research. I am dually appointed at
the University of Michigan and Ann Arbor VA and have held the ACR-RRF CIFA to assess quality of life in patients with gout and evaluate the gaps in treatment and knowledge. I served as a Co-I for the NIH/NIAMS PROMIS effort to develop and validate the GI-Symptoms Scale. I have been involved with development of gout guidelines and quality measures at national (ACR) and international level (EULAR), G-CAN and OMERACT including the 2012 and 2020 ACR gout guidelines. My long term goals are to design patient and physician interventions that improve health outcomes for our patients with rheumatic diseases (RA, SSc, AOSD and Gout). To that order I have conducted several clinical trials in acute and chronic therapeutic agents such as sodium bicarbonate, anakinra, febuxostat, lesinurad, pegloticase, pegadricase and now, IL-18 inhibition. I have successfully studied the effect of mycophenolate mofetil in reducing immunogenicity of pegloticase in severe tophaceous gout. My longstanding interest in PRO research has led me to develop focused expertise this field where I can positively impact patients' lives. So I have developed a patient-centric educational platform, MyGoutCare, to serve as a readily available resource for patients with gout (elbow support) at Michigan Medicine.
AVALO (Individual(s) Involved: Self; Ongoing): Grant/Research Support; DYVE (Individual(s) Involved: Self; Ongoing): Consultant, Grant/Research Support; Horizon (Individual(s) Involved: Self; Ongoing): Consultant, Grant/Research Support; Selecta (Individual(s) Involved: Self; Ongoing): Grant/Research Support
Saturday, November 12, 2022
5:00 PM – 5:45 PM Eastern Time
Sunday, November 13, 2022
10:30 AM – 11:30 AM Eastern Time
Monday, November 14, 2022
1:00 PM – 3:00 PM Eastern Time
